Gliptinext 20mg Tablet contains Teneligliptin 20mg, a potent and selective dipeptidyl peptidase-4 (DPP-4) inhibitor indicated for the management of type 2 diabetes mellitus. By inhibiting the DPP-4 enzyme, Teneligliptin prolongs the activity of incretin hormones such as GLP-1 and GIP, which enhance glucose-dependent insulin secretion and suppress glucagon release, thereby improving glycemic control. Gliptinext is typically prescribed as monotherapy or as an adjunct to diet and exercise when glycemic targets are not achieved with other antidiabetic agents. It may also be used in combination with other oral hypoglycemic drugs or insulin. The tablet is administered orally, with a recommended dose of 20mg once daily, which may be adjusted based on clinical response and tolerability. Teneligliptin has demonstrated a favorable safety profile, with a low risk of hypoglycemia when used alone and minimal impact on body weight. Common adverse effects include nasopharyngitis, headache, and gastrointestinal disturbances, though these are generally mild and transient. Gliptinext should be used cautiously in patients with renal or hepatic impairment, and regular monitoring of blood glucose levels is advised to optimize therapeutic outcomes.